Products could reach $100+ M in annual sales

once all the generics are launched which is expected within 18 months . IDT will reach deep profitability quickly because of its very low burn-rate . Management says more Product acqusition is planned . The new Management is doing good job  to date and the new  business strategy to start sell own Drugs is excellent . Patience will payoff big time here .GL



As announced to the ASX on 3 November 2014, the new product suite comprises 23 tablet and capsule products for conditions including Parkinson’s Disease,depression, infection,hypertension and pain. The total current annual global market for these products in these presentations is approximately $460 million (IMS).


The Abbreviated New Drug Application (ANDA) submission for Temozolomide is the first of IDT’s generic filings (ASX announcement 18 November 2013). It has now been accepted for
review by the United States Food and Drug Administration (FDA) and is currently progressing through the FDA’s review process.

Temozolomide is indicated for the treatment of melanoma and glioblastoma multiforme and had US sales of approximately USD 340 million in the 12 months ending 31 May 2014 .